Found niche pharma source. Is it legit?

LGG

LGG

Iron
Joined
Oct 13, 2025
Posts
195
Reputation
118
yo so found this seller from a friend, that sells a bunch of niche pharmaceuticals such as infigratinib, etc, im still awaiting a pricelist so i dont have all the details.

his profile pic says CORE so let me know if anyone has heard of this guy or group cause im not sure if this legit and i dont wanna get scammed. It has testing but not janoshik. im not gonna send the number cause i dont want anyone to think im promoting a source or something (name is steven here cause its what i named him as a contact ignore that.)
IMG 3578
 
hello steven
 
  • JFL
  • +1
Reactions: vernier, aids, karmacita901 and 3 others
hi steven
 
  • +1
Reactions: aids
yo so found this seller from a friend, that sells a bunch of niche pharmaceuticals such as infigratinib, etc, im still awaiting a pricelist so i dont have all the details.

his profile pic says CORE so let me know if anyone has heard of this guy or group cause im not sure if this legit and i dont wanna get scammed. It has testing but not janoshik. im not gonna send the number cause i dont want anyone to think im promoting a source or something (name is steven here cause its what i named him as a contact ignore that.)View attachment 4647606
infig is useless if you dont have the mutation
it inhibits an fgf thats needed for growth as well
kind soul told me this on my thread
 
infig is useless if you dont have the mutation
it inhibits an fgf thats needed for growth as well
kind soul told me this on my thread
ive not heard about the other fgfr type needed for growth, but on regard to the other point, atleast in mice fgfr3 inhibition grew longer bones, it was with TYRA 300, but we can assume the same with infigratinib:

TYRA-300 increases growth velocity and long bone growth in wild-type mice. To determine the in vivo effect of FGFR3 inhibition under normal physiologic conditions, TYRA-300 was tested in a growth velocity assay in wild-type mice (32). In this study, wild-type C57BL/6J mice were dosed orally with TYRA-300 once daily from 4 to 8 weeks of age. Previous work has demonstrated efficacy with TYRA-300 up to 18 mg/kg in oncology models (31). Based on the doses evaluated for infigratinib in oncology and ACH, a lower dose was thought to be more appropriate for long-term treatment of pediatric growth–related conditions. We therefore initially explored doses in the 8 to 14 mg/kg range in this model. Compared with the vehicle-treated group, there was a statistically significant increase in nasoanal length after treatment with 14 mg/kg TYRA-300 once daily (+7.3%, Figure 1A). Tail length and tibia and femur length also increased significantly and dose-dependently with both 12 mg/kg and 14 mg/kg TYRA-300 compared with vehicle treatment after 4 weeks of treatment (Figure 1, B–D). Specifically, after treatment with 12 mg/kg TYRA-300, the tibias were on average 3.9% longer than the tibias of mice that received treatment with vehicle, and the femurs were on average 5.0% longer after treatment; additionally, with 14 mg/kg TYRA-300, the tibias were 6.4% longer and the femurs were 8.2% longer. There was no difference in body weight among the treatment groups (data not shown). In addition, significant increases in nasoanal length and tibia and femur length were observed after treatment with 8 mg/kg and 10 mg/kg TYRA-300 (data not shown; P < 0.05). These results indicate that inhibition of wild-type FGFR3 signaling can effectively enhance growth velocity in a dose-dependent manner. While this model does not recapitulate any genetic growth disorder it does represent an accessible and facile tool for preliminary screening of compounds or treatments relative to the genetically modified models.
 
ive not heard about the other fgfr type needed for growth, but on regard to the other point, atleast in mice fgfr3 inhibition grew longer bones, it was with TYRA 300, but we can assume the same with infigratinib:

TYRA-300 increases growth velocity and long bone growth in wild-type mice. To determine the in vivo effect of FGFR3 inhibition under normal physiologic conditions, TYRA-300 was tested in a growth velocity assay in wild-type mice (32). In this study, wild-type C57BL/6J mice were dosed orally with TYRA-300 once daily from 4 to 8 weeks of age. Previous work has demonstrated efficacy with TYRA-300 up to 18 mg/kg in oncology models (31). Based on the doses evaluated for infigratinib in oncology and ACH, a lower dose was thought to be more appropriate for long-term treatment of pediatric growth–related conditions. We therefore initially explored doses in the 8 to 14 mg/kg range in this model. Compared with the vehicle-treated group, there was a statistically significant increase in nasoanal length after treatment with 14 mg/kg TYRA-300 once daily (+7.3%, Figure 1A). Tail length and tibia and femur length also increased significantly and dose-dependently with both 12 mg/kg and 14 mg/kg TYRA-300 compared with vehicle treatment after 4 weeks of treatment (Figure 1, B–D). Specifically, after treatment with 12 mg/kg TYRA-300, the tibias were on average 3.9% longer than the tibias of mice that received treatment with vehicle, and the femurs were on average 5.0% longer after treatment; additionally, with 14 mg/kg TYRA-300, the tibias were 6.4% longer and the femurs were 8.2% longer. There was no difference in body weight among the treatment groups (data not shown). In addition, significant increases in nasoanal length and tibia and femur length were observed after treatment with 8 mg/kg and 10 mg/kg TYRA-300 (data not shown; P < 0.05). These results indicate that inhibition of wild-type FGFR3 signaling can effectively enhance growth velocity in a dose-dependent manner. While this model does not recapitulate any genetic growth disorder it does represent an accessible and facile tool for preliminary screening of compounds or treatments relative to the genetically modified models.
yea no way im reading all that, how did you not realise that i said it doesnt work BECAUSE of it inhibiting another fgf
tyra 300 is legit tho
 
  • +1
Reactions: Sayori
yea no way im reading all that, how did you not realise that i said it doesnt work BECAUSE of it inhibiting another fgf
tyra 300 is legit tho
fgf1 and 2 arent needed for growth? correct me if jm wrong
 
  • +1
Reactions: birthdefect and LGG
yo so found this seller from a friend, that sells a bunch of niche pharmaceuticals such as infigratinib, etc, im still awaiting a pricelist so i dont have all the details.

his profile pic says CORE so let me know if anyone has heard of this guy or group cause im not sure if this legit and i dont wanna get scammed. It has testing but not janoshik. im not gonna send the number cause i dont want anyone to think im promoting a source or something (name is steven here cause its what i named him as a contact ignore that.)View attachment 4647606
Not tagging me even tho I gave you the source is criminal nigga
 
fgf1 and 2 arent needed for growth? correct me if jm wrong
fgf2 acts to hypertrophy the chondrocytes later, which you kinda need tbh at some point
 
  • +1
Reactions: infrainfra
fgf2 acts to hypertrophy the chondrocytes later, which you kinda need tbh at some point
is there any drug that inhibits only fgfr3? prolly not. our best option by far is infigatinib ?
 
fgf2 acts to hypertrophy the chondrocytes later, which you kinda need tbh at some point
we dont even want chondrocyte hypertrophy much, and even while inhibiting fgfr2 so it obviously works in achondroplasia people still
 
Last edited:
yo so found this seller from a friend, that sells a bunch of niche pharmaceuticals such as infigratinib, etc, im still awaiting a pricelist so i dont have all the details.

his profile pic says CORE so let me know if anyone has heard of this guy or group cause im not sure if this legit and i dont wanna get scammed. It has testing but not janoshik. im not gonna send the number cause i dont want anyone to think im promoting a source or something (name is steven here cause its what i named him as a contact ignore that.)View attachment 4647606
Yo that’s my boy Steven
 
ive not heard about the other fgfr type needed for growth, but on regard to the other point, atleast in mice fgfr3 inhibition grew longer bones, it was with TYRA 300, but we can assume the same with infigratinib:

TYRA-300 increases growth velocity and long bone growth in wild-type mice. To determine the in vivo effect of FGFR3 inhibition under normal physiologic conditions, TYRA-300 was tested in a growth velocity assay in wild-type mice (32). In this study, wild-type C57BL/6J mice were dosed orally with TYRA-300 once daily from 4 to 8 weeks of age. Previous work has demonstrated efficacy with TYRA-300 up to 18 mg/kg in oncology models (31). Based on the doses evaluated for infigratinib in oncology and ACH, a lower dose was thought to be more appropriate for long-term treatment of pediatric growth–related conditions. We therefore initially explored doses in the 8 to 14 mg/kg range in this model. Compared with the vehicle-treated group, there was a statistically significant increase in nasoanal length after treatment with 14 mg/kg TYRA-300 once daily (+7.3%, Figure 1A). Tail length and tibia and femur length also increased significantly and dose-dependently with both 12 mg/kg and 14 mg/kg TYRA-300 compared with vehicle treatment after 4 weeks of treatment (Figure 1, B–D). Specifically, after treatment with 12 mg/kg TYRA-300, the tibias were on average 3.9% longer than the tibias of mice that received treatment with vehicle, and the femurs were on average 5.0% longer after treatment; additionally, with 14 mg/kg TYRA-300, the tibias were 6.4% longer and the femurs were 8.2% longer. There was no difference in body weight among the treatment groups (data not shown). In addition, significant increases in nasoanal length and tibia and femur length were observed after treatment with 8 mg/kg and 10 mg/kg TYRA-300 (data not shown; P < 0.05). These results indicate that inhibition of wild-type FGFR3 signaling can effectively enhance growth velocity in a dose-dependent manner. While this model does not recapitulate any genetic growth disorder it does represent an accessible and facile tool for preliminary screening of compounds or treatments relative to the genetically modified models.
Dnr
 
shlould i be low inhib and order rn? icl im just skeptical no one else has heard of this seller
I mean I can show you that I ordered but idrc wheter u think theyre legit or not
 

Similar threads

LGG
Replies
6
Views
101
AscendMEincels
AscendMEincels
hopelessromanticc
Replies
6
Views
212
Soter
Soter
chudpiller
Replies
84
Views
3K
heraa
heraa
hej1377
Replies
13
Views
510
Histy
Histy

Users who are viewing this thread

  • js.rm.atp
  • aus.peptides
Back
Top